Results 141 to 150 of about 92,035 (255)

From haemostasis to immunity: The expanding frontiers of platelet biology

British Journal of Haematology, EarlyView.
Platelets are versatile cells whose functions extend far beyond haemostasis and thrombosis, actively regulating innate and adaptive immunity, angiogenesis, lymphangiogenesis, liver regeneration, atherosclerosis and tumour metastasis. This demonstrates their central role in various physiological processes and multiple life‐threatening diseases ...
Xun Grace Wu, Nicole Tomei, Heyu Ni
wiley   +1 more source

Major Histocompatibility Complex Class I Matching is Necessary but not Sufficient for Tolerance Induction to Vascularized Composite Allografts After Donor Hematopoietic Cell Transplantation. [PDF]

Transplant Direct
Manell E, Gunes ME, Merl S, Patwardhan S, Chauhan I, Hong J, Chen B, Jordache P, Almesalmy A, Ekanayake-Alper D, Hajosi D, Husain S, Wuu CS, Wright M, Bogue J, Rohde C, Shanmugarajah K, Cetrulo CL, Sachs DH, Weiner J.   +19 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

From viral drift to tumor drift: why cancer immunotherapy needs B cells and dynamic adaptation. [PDF]

J Immunother Cancer
Liu Z.
europepmc   +1 more source

Anti-GBM disease after nephrectomy for xanthogranulomatous pyelonephritis in a patient expressing HLA DR15 major histocompatibility antigens: a case report. [PDF]

Clin Nephrol Case Stud, 2015
O'Hagan E, Mallett T, Convery M, McKeever K.   +3 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

LASS I MAJOR HISTOCOMPATIBILITY ANTIGENS IN PRIMARY BILIARY CIRRHOSIS

The Turkish Journal of Gastroenterology, 1994
Ömer ÖZÜTEMİZ, Hayri ÖZSAN, Sevgi MİR, Tankut İLTER   +3 more
doaj  

MICA is a histocompatibility antigen in transplantation

American Journal of Transplantation, 2022
openaire   +2 more sources

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy. [PDF]

Curr Opin Immunol
Shaffer BC, Shaw BE.
europepmc   +1 more source